World Library  
Flag as Inappropriate
Email this Article

Alpha-2 blocker

Article Id: WHEBN0018484744
Reproduction Date:

Title: Alpha-2 blocker  
Author: World Heritage Encyclopedia
Language: English
Subject: Alpha blocker
Publisher: World Heritage Encyclopedia

Alpha-2 blocker

α2-blockers are a subset of the alpha blocker class of drugs and are antagonists to the α2 adrenergic receptor. They are mainly used in research, finding limited clinical application in human medicine.


Historically, yohimbine was used as an aphrodisiac, and is still sometimes used in veterinary medicine (although now largely replaced by atipamezole) for reversing the effects of alpha-2 agonists such as medetomidine which are used as sedatives during surgery. [1]

α2-blockers have found medical uses in treating depression; the tetracyclic antidepressants mianserin and mirtazapine are α2-blockers, although their efficacy as antidepressants may come from their activity at other receptor sites.

Mechanistically, α2-blockers significantly increase adrenergic, dopaminergic and serotonergic neurotransmitters, and induce insulin secretion and decreases blood sugar levels.

Withdrawal from α2-blockers can be difficult or dangerous as the global down regulation of neurotransmitters may cause symptoms of depression and other neurological problems, and increased blood sugar levels together with decreased insulin sensitivity can cause diabetes. Reduced microcirculation together with adrenaline supersensitivity in organs such as liver can also be difficult problem when withdrawing from adrenergic blockers.


Examples include atipamezole,[2] efaroxan, idazoxan,[3] yohimbine, and rauwolscine.


  1. ^ Lemke, KA (June 2004). "Perioperative use of selective alpha-2 agonists and antagonists in small animals.". The Canadian veterinary journal. La revue veterinaire canadienne 45 (6): 475–80.  
  2. ^ Haapalinna A, Leino T, Heinonen E (November 2003). "The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats". Naunyn Schmiedebergs Arch. Pharmacol. 368 (5): 342–51.  
  3. ^ Chopin P, Colpaert FC, Marien M (February 1999). "Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway". J. Pharmacol. Exp. Ther. 288 (2): 798–804.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.